Previous 10 | Next 10 |
Headquartered in the Cayman Islands, Theravance Biopharma ( TBPH ) is a biopharmaceutical company focused on therapeutic areas such as infectious, respiratory, gastrointestinal, cardiovascular, renal, inflammation and immunology diseases. The company attributes its current revenues to the ...
DUBLIN , Oct. 30, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended September 30, 2018 and provide a business update after market close on Tuesday, No...
DUBLIN , Oct. 22, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported the results from the exploratory Phase 1b study of the gut-selective pan-Janus kinase (JAK) inhibitor TD-1473 in an oral presentation as part of...
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that positive new data from multiple studies of YUPELRI ™ (re...
DUBLIN , Oct. 10, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that the results from the Phase 1b study of TD-1473 in patients with moderately-to-severely active ulcerative colitis have been selected for or...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Oct. 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that data from studies of YUPELRI ™ (revefenacin) will be prese...
DUBLIN , Oct. 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that positive new data from multiple studies of VIBATIV ® (telavancin) were presented at IDWeek ™ 2018, which was held in San Franc...
"Never attribute to malice that which can be adequately explained by stupidity." - Robert J. Hanlon It has been two months since we positively profiled Theravance Biopharma ( TBPH ) . The stock is up some 35% since then and has been particularly strong over the past couple of weeks. Wit...
WASHINGTON , Oct. 3, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, announced today that 16 of its member companies will present data from their clinical a...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...